drugset / Trial / NCT00055185

Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients

NCT00055185 ↗

Phase 2 Completed 24 enrolled Progenics Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.

Timeline

Start
2003-04
Primary completion
—
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PRO 542 Protein / enzyme biologic — —

Indications